Pharmacy closures are occurring at an alarming rate and threatening a large loss of access to essential healthcare in many US neighborhoods. | Forefront Emily Gravlee, et al. | @USCMann, @olemisspharmacy, @USCSchaeffer https://t.co/q23qgxeLru

While cannabis may soon be considered a lower-risk drug, a USC Schaeffer white paper highlights growing evidence of health risks from heavy or long-term use. The authors argue federal regulations are needed to protect consumers & promote responsible use.

Even the most advanced medical technology means little if patients in need can’t access it, USC Schaeffer's Darius Lakdawalla told lawmakers. Forward-thinking regulatory reform can promote tech that makes good health more accessible & affordable. 👇 https://t.co/ETTzmuxYVv

#Alzheimers could drive families & the US toward fiscal disaster, warn USC Schaeffer’s Joe Grogan & Ryan Long in @RealClearHealth. Smart policy choices now to boost prevention, early detection & innovation can add years of healthy life & protect budgets.

📢Making #Alzheimers clinical trials faster, stronger and more representative. Our new Clinical Trial Knowledge Hub shares lessons from the field and key insights on what works. Explore here: https://t.co/Rg7poDl4Ya

More money can't fix the ACA, but there's a better way to cover every American without increasing costs, writes USC Schaeffer's Dana Goldman. Meet the USA Plan: ✅Basic protection for all ✅Income-based deductibles ✅No-cost preventive care Read more:

Newer, transparent #PBMs are gaining some ground in a marketplace dominated by 3 major firms. But as USC Schaeffer’s Neeraj Sood tells @modrnhealthcr @Tong_Thoughts, the fate of these alternative PBMs is still tied to the Big 3.

The declining prices of anti-obesity medications show the power of competition and transparency in the pharmaceutical market, USC Schaeffer’s Dana Goldman writes in the @WSJ.

USC Schaeffer Scholar @DrWmPadula spoke with @Reuters about the new round of #Medicare-negotiated drug prices announced yesterday.

📅 Meeting the urgent need for #Alzheimers treatments requires a stronger, more efficient system for recruiting patients into trials. Join the USC Clinical Trial Recruitment Lab on Dec. 4 to hear from leading experts. Info and registration: https://t.co/zM75kzU4zJ

The 340B program was designed to help uninsured patients and poorer hospitals. Poorer hospitals rely on the program yet receive disproportionately little from the program compared to wealthy entities due to its inherently faulty design. Poorer hospitals get less, incentivizes

Prescription drug ads get blamed for a lot. But the evidence for banning them is actually thin, USC Schaeffer’s Neeraj Sood writes in @JAMAHealthForum.

How hard is it to navigate rising costs and narrowing options in #Medicare Part D? 🎧Listen to @tradeoffspod, as Schaeffer Center Co-Director Erin Trish helps her mother sort through the rapidly shifting marketplace.

📅 From AI to blood biomarkers, new tools are poised to transform #Alzheimers clinical trial recruitment. Join USC’s Clinical Trial Recruitment Lab on Dec. 4 in San Diego for a symposium on faster, more efficient, and inclusive trials. Register here: https://t.co/zM75kzU4zJ

Five years after Congress banned #SurpriseBills, patients are still waiting on some key cost transparency protections promised in the law. USC Schaeffer Scholar Erin Duffy in @Health_Affairs Forefront argues patients can't afford further delays.

The White House's efforts to expand access to anti-obesity medications address a critical public health challenge. @USCSchaeffer research demonstrating the health and economic benefits of broader coverage helped inform the move.

The White House’s deals on anti-obesity medications could have a ripple effect: They may encourage more insurers to offer coverage, USC Schaeffer’s Darius Lakdawalla tells @CNBC.

People with #diabetes are living healthier lives due to medical advances over the past few decades—but surprisingly, their workforce participation hasn’t improved. USC Schaeffer's Jack Chapel dives into this “diabetes paradox" on the @AcademicMinute.

Expanding #Medicare coverage of anti-obesity medications would be one of the most effective public health investments the U.S. could make, USC Schaeffer research shows. Our scholars have identified ways it can be done affordably.

While Congress continues to weigh #PBM reform, many states have passed laws this year targeting middlemen practices. USC Schaeffer's Geoffrey Joyce tells @stateline_news these efforts can help bring down patient costs.